Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer

  title={Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer},
  author={C. Mahler and J. Verhelst and L. Denis},
  journal={Clinical Pharmacokinetics},
  • C. Mahler, J. Verhelst, L. Denis
  • Published 1998
  • Medicine
  • Clinical Pharmacokinetics
  • Prostatic cancer is the second most common cause of cancer death in males. Treatment by radical prostatectomy and radiotherapy is useful in the early stages of the disease. Whenever metastases occur, patients are usually treated by surgical (orchidectomy) or medical [gonadotropin releasing hormone (GnRH) analogue] castration. This form of treatment is, however, associated with unwanted adverse effects, such as flushing, loss of libido and potency and all patients ultimately escape therapy after… CONTINUE READING
    71 Citations
    Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer.
    • 8
    • PDF
    Non-steroidal anti-androgens in prostate cancer - current treatment practice
    • 3
    Antiandrogen monotherapy: indications and results.
    • 52
    An evaluation of bicalutamide in the treatment of prostate cancer
    • 54
    Androgen Deprivation Therapy for Prostate Cancer.
    • V. Pagliarulo
    • Medicine, Biology
    • Advances in experimental medicine and biology
    • 2018
    • 80
    Bicalutamide (Casodex®) in the treatment of prostate cancer
    • Y. Fradet
    • Medicine
    • Expert review of anticancer therapy
    • 2004
    • 69
    Recent developments in antiandrogens and selective androgen receptor modulators
    • 62


    Defining the role of antiandrogens in the treatment of prostate cancer.
    • 6
    A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    • 1,356
    New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
    • 272
    Withdrawal phenomenon with the antiandrogen casodex.
    • P. Nieh
    • Medicine
    • The Journal of urology
    • 1995
    • 78
    Ocular toxicity of Anandron in patients treated for prostatic cancer.
    • 30
    • PDF
    The antiandrogen withdrawal syndrome
    • 63
    A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.
    • 89
    Indications for Antiandrogen Treatment in Prostate Cancer
    • 2